Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Exclusions
Mortality
ICU
Hospitalization
Serious outcomes
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Metformin
Bamlanivimab Molnupiravir
Bromhexine Nigella Sativa
Budesonide Nitazoxanide
Casirivimab/i.. Povidone-Iod..
Colchicine Probiotics
Conv. Plasma Proxalutamide
Curcumin Quercetin
Favipiravir Remdesivir
Fluvoxamine Sotrovimab
Hydroxychloro.. Vitamin A
Iota-carragee.. Vitamin C
Ivermectin Vitamin D
Melatonin Zinc

Other Adoption
Outcomes in COVID-19 colchicine studies
00.250.50.7511.251.51.752+Deftereos (RCT)77%0.23 [0.03-1.97]death1/554/50Improvement, RR [CI]TreatmentControlLopes (DB RCT)80%0.20 [0.01-4.03]death0/362/36Brunetti (PSM)73%0.27 [0.08-0.89]death3/3311/33Scarsi85%0.15 [0.06-0.37]death122 (n)140 (n)Salehzadeh (RCT)23%0.77 [0.66-0.90]hosp. time50 (n)50 (n)Pinzón35%0.65 [0.34-1.21]death14/14523/156Sandhu42%0.58 [0.40-0.85]death16/3463/78Rodriguez-Nava6%0.94 [0.61-1.47]death16/5285/261Tardif (DB RCT)44%0.56 [0.19-1.67]death5/2,2359/2,253Horby (RCT)-1%1.01 [0.93-1.10]death1,173/5,6101,190/5,730Gaitán-Dua.. (RCT)19%0.81 [0.48-1.35]death22/15328/161CT​1Dorward (RCT)-30%1.30 [0.42-3.84]hosp./death6/1564/133Tau​2 = 0.08; I​2 = 73.9%Late treatment31%0.69 [0.54-0.88]1,256/8,6811,419/9,08131% improvementAll studies31%0.69 [0.54-0.88]1,256/8,6811,419/9,08131% improvement12 colchicine COVID-19 studiesc19colchicine.com Oct 16, 20211 CT: study uses combined treatmentTau​2 = 0.08; I​2 = 73.9%; Z = 3.02Effect extraction pre-specifiedFavors colchicineFavors control 00.250.50.7511.251.51.752+Deftereos (RCT)77%0.23 [0.03-1.97]death1/554/50Improvement, RR [CI]TreatmentControlLopes (DB RCT)80%0.20 [0.01-4.03]death0/362/36Brunetti (PSM)73%0.27 [0.08-0.89]death3/3311/33Scarsi85%0.15 [0.06-0.37]death122 (n)140 (n)Salehzadeh (RCT)23%0.77 [0.66-0.90]hosp. time50 (n)50 (n)Pinzón35%0.65 [0.34-1.21]death14/14523/156Sandhu42%0.58 [0.40-0.85]death16/3463/78Tardif (DB RCT)44%0.56 [0.19-1.67]death5/2,2359/2,253Horby (RCT)-1%1.01 [0.93-1.10]death1,173/5,6101,190/5,730Gaitán-Dua.. (RCT)19%0.81 [0.48-1.35]death22/15328/161CT​1Dorward (RCT)-30%1.30 [0.42-3.84]hosp./death6/1564/133Tau​2 = 0.08; I​2 = 76.3%Late treatment35%0.65 [0.50-0.85]1,240/8,6291,334/8,82035% improvementAll studies35%0.65 [0.50-0.85]1,240/8,6291,334/8,82035% improvement11 colchicine COVID-19 studies after exclusionsc19colchicine.com Oct 16, 20211 CT: study uses combined treatmentTau​2 = 0.08; I​2 = 76.3%; Z = 3.12Effect extraction pre-specifiedFavors colchicineFavors control 00.250.50.7511.251.51.752+Deftereos (RCT)77%0.23 [0.03-1.97]1/554/50Improvement, RR [CI]TreatmentControlLopes (DB RCT)80%0.20 [0.01-4.03]0/362/36Brunetti (PSM)73%0.27 [0.08-0.89]3/3311/33Scarsi85%0.15 [0.06-0.37]122 (n)140 (n)Pinzón35%0.65 [0.34-1.21]14/14523/156Sandhu42%0.58 [0.40-0.85]16/3463/78Rodriguez-Nava6%0.94 [0.61-1.47]16/5285/261Tardif (DB RCT)44%0.56 [0.19-1.67]5/2,2359/2,253Horby (RCT)-1%1.01 [0.93-1.10]1,173/5,6101,190/5,730Gaitán-Dua.. (RCT)19%0.81 [0.48-1.35]22/15328/161CT​1Tau​2 = 0.17; I​2 = 74.5%Late treatment40%0.60 [0.42-0.86]1,250/8,4751,415/8,89840% improvementAll studies40%0.60 [0.42-0.86]1,250/8,4751,415/8,89840% improvement10 colchicine COVID-19 mortality resultsc19colchicine.com Oct 16, 20211 CT: study uses combined treatmentTau​2 = 0.17; I​2 = 74.5%; Z = 2.82Favors colchicineFavors control 00.250.50.7511.251.51.752+Lopes (DB RCT)50%0.50 [0.10-2.56]2/364/36Improvement, RR [CI]TreatmentControlGaitán-Dua.. (RCT)1%0.99 [0.56-1.74]19/11318/114CT​1Tau​2 = 0.00; I​2 = 0.0%Late treatment9%0.91 [0.53-1.59]21/14922/1509% improvementAll studies9%0.91 [0.53-1.59]21/14922/1509% improvement2 colchicine COVID-19 ICU resultsc19colchicine.com Oct 16, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 0.31Favors colchicineFavors control 00.250.50.7511.251.51.752+Salehzadeh (RCT)23%0.77 [0.66-0.90]hosp. time50 (n)50 (n)Improvement, RR [CI]TreatmentControlTardif (DB RCT)20%0.80 [0.61-1.03]hosp.101/2,235128/2,253Tau​2 = 0.00; I​2 = 0.0%Late treatment22%0.78 [0.68-0.89]101/2,285128/2,30322% improvementAll studies22%0.78 [0.68-0.89]101/2,285128/2,30322% improvement2 colchicine COVID-19 hospitalization resultsc19colchicine.com Oct 16, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 3.72Favors colchicineFavors control 00.250.50.7511.251.51.752+Deftereos (RCT)77%0.23 [0.03-1.97]death1/554/50Improvement, RR [CI]TreatmentControlLopes (DB RCT)80%0.20 [0.01-4.03]death0/362/36Brunetti (PSM)73%0.27 [0.08-0.89]death3/3311/33Scarsi85%0.15 [0.06-0.37]death122 (n)140 (n)Pinzón35%0.65 [0.34-1.21]death14/14523/156Sandhu42%0.58 [0.40-0.85]death16/3463/78Rodriguez-Nava6%0.94 [0.61-1.47]death16/5285/261Tardif (DB RCT)44%0.56 [0.19-1.67]death5/2,2359/2,253Horby (RCT)-1%1.01 [0.93-1.10]death1,173/5,6101,190/5,730Gaitán-Dua.. (RCT)19%0.81 [0.48-1.35]death22/15328/161CT​1Dorward (RCT)-30%1.30 [0.42-3.84]hosp./death6/1564/133Tau​2 = 0.16; I​2 = 71.9%Late treatment37%0.63 [0.45-0.88]1,256/8,6311,419/9,03137% improvementAll studies37%0.63 [0.45-0.88]1,256/8,6311,419/9,03137% improvement11 colchicine COVID-19 serious outcomesc19colchicine.com Oct 16, 20211 CT: study uses combined treatmentTau​2 = 0.16; I​2 = 71.9%; Z = 2.69Effect extraction pre-specifiedFavors colchicineFavors control 00.250.50.7511.251.51.752+Deftereos (RCT)77%0.23 [0.03-1.97]death1/554/50Improvement, RR [CI]TreatmentControlLopes (DB RCT)80%0.20 [0.01-4.03]death0/362/36Salehzadeh (RCT)23%0.77 [0.66-0.90]hosp. time50 (n)50 (n)Tardif (DB RCT)44%0.56 [0.19-1.67]death5/2,2359/2,253Horby (RCT)-1%1.01 [0.93-1.10]death1,173/5,6101,190/5,730Gaitán-Dua.. (RCT)19%0.81 [0.48-1.35]death22/15328/161CT​1Dorward (RCT)-30%1.30 [0.42-3.84]hosp./death6/1564/133Tau​2 = 0.03; I​2 = 57.1%Late treatment14%0.86 [0.69-1.06]1,207/8,2951,237/8,41314% improvementAll studies14%0.86 [0.69-1.06]1,207/8,2951,237/8,41314% improvement7 colchicine COVID-19 Randomized Controlled Trialsc19colchicine.com Oct 16, 20211 CT: study uses combined treatmentTau​2 = 0.03; I​2 = 57.1%; Z = 1.40Effect extraction pre-specifiedFavors colchicineFavors control 00.250.50.7511.251.51.752+Deftereos (RCT)77%0.23 [0.03-1.97]1/554/50Improvement, RR [CI]TreatmentControlLopes (DB RCT)80%0.20 [0.01-4.03]0/362/36Tardif (DB RCT)44%0.56 [0.19-1.67]5/2,2359/2,253Horby (RCT)-1%1.01 [0.93-1.10]1,173/5,6101,190/5,730Gaitán-Dua.. (RCT)19%0.81 [0.48-1.35]22/15328/161CT​1Tau​2 = 0.02; I​2 = 15.2%Late treatment8%0.92 [0.72-1.17]1,201/8,0891,233/8,2308% improvementAll studies8%0.92 [0.72-1.17]1,201/8,0891,233/8,2308% improvement5 colchicine COVID-19 RCT mortality resultsc19colchicine.com Oct 16, 20211 CT: study uses combined treatmentTau​2 = 0.02; I​2 = 15.2%; Z = 0.69Favors colchicineFavors control 00.250.50.7511.251.51.752+Deftereos (RCT)77%0.23 [0.03-1.97]death1/554/50Improvement, RR [CI]TreatmentControlLopes (DB RCT)80%0.20 [0.01-4.03]death0/362/36Brunetti (PSM)73%0.27 [0.08-0.89]death3/3311/33Scarsi85%0.15 [0.06-0.37]death122 (n)140 (n)Sandhu42%0.58 [0.40-0.85]death16/3463/78Rodriguez-Nava6%0.94 [0.61-1.47]death16/5285/261Tardif (DB RCT)44%0.56 [0.19-1.67]death5/2,2359/2,253Tau​2 = 0.26; I​2 = 63.0%Late treatment56%0.44 [0.26-0.76]41/2,567174/2,85156% improvementAll studies56%0.44 [0.26-0.76]41/2,567174/2,85156% improvement7 colchicine COVID-19 peer reviewed trialsc19colchicine.com Oct 16, 2021Tau​2 = 0.26; I​2 = 63.0%; Z = 2.97Effect extraction pre-specifiedFavors colchicineFavors control 00.250.50.7511.251.51.752+Deftereos (RCT)77%0.23 [0.03-1.97]death1/554/50Improvement, RR [CI]TreatmentControlDeftereos (RCT)82%0.18 [0.02-1.50]ventilation1/555/50Deftereos (RCT)87%0.13 [0.01-0.97]progression1/557/50Lopes (DB RCT)80%0.20 [0.01-4.03]death0/362/36Lopes (DB RCT)50%0.50 [0.10-2.56]ICU2/364/36Brunetti (PSM)73%0.27 [0.08-0.89]death3/3311/33Brunetti (PSM)73%0.27 [0.08-0.89]no disch.3/3311/33Scarsi85%0.15 [0.06-0.37]death122 (n)140 (n)Salehzadeh (RCT)23%0.77 [0.66-0.90]hosp. time50 (n)50 (n)Pinzón35%0.65 [0.34-1.21]death14/14523/156Sandhu42%0.58 [0.40-0.85]death16/3463/78Sandhu53%0.47 [0.33-0.67]ventilation16/3468/68Sandhu42%0.58 [0.40-0.85]no disch.16/3463/78Rodriguez-Nava6%0.94 [0.61-1.47]death16/5285/261Tardif (DB RCT)44%0.56 [0.19-1.67]death5/2,2359/2,253Tardif (DB RCT)47%0.53 [0.25-1.09]ventilation11/2,23521/2,253Tardif (DB RCT)20%0.80 [0.61-1.03]hosp.101/2,235128/2,253Horby (RCT)-1%1.01 [0.93-1.10]death1,173/5,6101,190/5,730Gaitán-Dua.. (RCT)19%0.81 [0.48-1.35]death22/15328/161CT​1Gaitán-Dua.. (RCT)15%0.85 [0.68-1.06]ventilation27/13627/140CT​1Gaitán-Dua.. (RCT)1%0.99 [0.56-1.74]ICU19/11318/114CT​1Dorward (RCT)-30%1.30 [0.42-3.84]hosp./death6/1564/133Dorward (RCT)22%0.78 [0.30-1.73]hosp./death6/156119/1,145Dorward (RCT)6%0.94 [0.79-1.11]progression102/15683/120Dorward (RCT)6%0.94 [0.72-1.24]no recov.156 (n)133 (n)colchicine COVID-19 outcomesc19colchicine.com Oct 16, 2021Favors colchicineFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit